Hiroki Ozawa

11PUBLICATIONS
43CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer cell biologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Social epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 05, 2026
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.

|Oct 14, 2025
Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.

Hiroki Ozawa, Kazuki Takahashi, Tomoki Motegi

|Aug 08, 2025
Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells.

Naoki Haratake, Shinkichi Takamori, Hideko Isozaki

|Aug 06, 2025
MUC1-C auto-regulatory complex with EBNA1 is responsible for latent Epstein-Barr virus-associated gastric cancer progression.

Hiroki Ozawa, Yin Wang, Henry G Withers

|May 13, 2024
XIST and MUC1-C form an auto-regulatory pathway in driving cancer progression.

Keyi Wang, Atrayee Bhattacharya, Naoki Haratake

|Apr 15, 2024
Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas.

Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya

Pageof 2

Frequent Collaborators

7 joint publications

Donald W Kufe

4 joint publications

Mark D Long

2 joint publications

Tomoharu Yoshizumi

2 joint publications

Keyi Wang